

# Beaumont

Colleagues,

As you may be aware, the SARS-CoV-2 Omicron subvariant BA.2 has become the predominant strain circulating throughout the country, including Michigan. As on so many other occasions during the last two years, this requires another pivot in treatment plans. Sotrovimab, which has been our monoclonal antibody of choice since the beginning of 2022, is thought to be less effective against BA.2, and as such, the state of Michigan is stopping distribution of this agent.

Another mAb, bebtelovimab, is available and appears to have activity against the BA.2 variant. Many details around this agent (indications, age/weight criteria, adverse reactions, observation time, etc.) are similar to what you're familiar with from the other mAbs, though it does have a few unique characteristics:

- Only approved for use within seven days of symptom onset
- Is administered as an IV injection over 30 seconds
- Only authorized for use in patients for whom other options (e.g. Paxlovid) are either inaccessible or not appropriate

There is very little clinical data available for this agent, and no data comparing it to a placebo in patients at high risk for severe disease. The rate of hospitalization in these patients who received bebtelovimab was 1.7%, similar to data from evaluation of other mAbs. The [bebtelovimab fact sheet](#) and [order form](#) are available, and it can also be ordered in Epic/*one*Chart, similarly to how you've ordered these if interested in perusing. It should be available for patients at Beaumont beginning the week of April 11.

It's important to emphasize that of the three options for outpatient treatment of COVID-19 (Paxlovid, molnupiravir and bebtelovimab), Paxlovid should be the preferred option, both because of its availability and the amount of clinical data it has. It can be ordered in Epic/*one*Chart and is available at all Meijer pharmacies in Michigan as well as several others. A current list is available within the Epic/*one*Chart order. For patients who are not eligible for Paxlovid due to drug interactions or comorbid conditions, then bebtelovimab or molnupiravir may be viable options. Please view the [Paxlovid fact sheet here](#).

Thanks as always for your continued efforts in combating COVID-19.

Paul Chittick, M.D.  
Section Head, Infectious Diseases &  
International Medicine  
Beaumont Hospital, Royal Oak  
[Paul.chittick@beaumont.edu](mailto:Paul.chittick@beaumont.edu)

*This message was sent to all Beaumont physicians.*